期刊
JOURNAL OF INTERNAL MEDICINE
卷 275, 期 4, 页码 364-381出版社
WILEY
DOI: 10.1111/joim.12204
关键词
multiple sclerosis; immunomodulatory therapy; biological therapies; randomized controlled trial
资金
- Biogen Idec
Multiple sclerosis (MS) is primarily an autoimmune disease of the central nervous system, but also encompasses prominent neurodegenerative aspects. A significant proportion of MS patients will develop neurological disability over time and up until recently treatment options have been limited. However, MS treatment is now at a stage of rapid progress, with several new drugs that have reached the market or will be launched in the near future. This provides new opportunities for individualized treatment, but also creates new challenges regarding monitoring of disease activity, long-term safety issues and efficacy, not least in patients with progressive disease.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据